LOGIN  |  REGISTER
C4 Therapeutics

RadNet to Enter the Houston, Texas Market through Platform Acquisition of Houston Medical Imaging

February 27, 2024 | Last Trade: US$82.01 0.84 -1.01

LOS ANGELES, Feb. 27, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a definitive agreement to purchase the assets of seven imaging centers in the greater Houston, Texas metropolitan area from Houston Medical Imaging, LLC. Upon closing the acquisition, which is anticipated to occur during the second quarter, 2024, RadNet will be entering its first new market since 2020. The acquisition is subject to customary closing conditions.

The seven centers, once acquired, will continue to operate under the Houston Medical Imaging brand, and will offer multi-modality services, including MRI, CT, PET/CT, X-ray, ultrasound, mammography and other procedures. During 2023, these seven centers collectively performed over 135,000 procedures and produced over $28 million of Revenue.

RadNet’s President and Chief Executive Officer, Howard Berger, MD, explained, “The Houston metropolitan marketplace, encompassing about 7.3 million people, is the fourth most populous city and the second fastest growing metropolitan area in the United States. We believe this initial acquisition forms a strong platform from which to grow a new core network for RadNet. We are confident of the opportunity for further acquisitions, de novo build-outs, health system partnerships and other means of expansion, which include bringing our AI and leading edge clinical and operating digital health solutions to the patient and referring communities of greater Houston.”

Dr. Berger added, “We are very intentional and methodical in our approach to entering new markets. As is the case with other markets, in Houston, we will be committed to expanding patient access and services. The Houston market exhibits many of the characteristics that have permitted us to be successful in other RadNet core geographies. We welcome the over 20 affiliated radiologists and the approximately 140 additional team members who currently support these Houston facilities, and look forward to growing this practice with them in the near future.”

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has approximately 9,000 employees. For more information, visit http://www.radnet.com

Forward Looking Statements

This press release contains certain statements that constitute "forward-looking statements" within the meaning of federal securities laws, including statements regarding the effects of the proposed transaction. These statements are based on the assumptions and beliefs of RadNet, Inc. management in light of the information currently available to it. Such statements are indicated by words or phrases such as "accelerate," "create," "committed," "confident," "continue," "deliver," "driving," "expect," "future," "guidance," "positioned," "strategy," "target," "synergies," "trends," and "will." Various uncertainties and other factors could cause actual results to differ materially from those contained in the forward-looking statements. These include the specific risk factors identified in "Risk Factors" in RadNet, Inc.’s annual report on Form 10-K for the last fiscal year and any subsequent filings, as well as the following:

the expected timing and likelihood of completion of the proposed transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory clearance of the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the acquisition agreement; the inability to consummate the proposed transaction due to the failure to satisfy other conditions to complete the proposed transaction; the ability to identify and recognize the anticipated benefits of the proposed transaction, including anticipated revenue and procedural volumes; and the ability of RadNet, Inc. to successfully integrate the business and related operations; risks related to the potential impact of general economic, political and market factors on the companies or the proposed transaction. The ability of RadNet, Inc. to achieve the goals for the proposed transaction may also be affected by its ability to manage the factors identified above.

The forward-looking statements by RadNet, Inc. included in this press release speak only as of the date the statements were made. RadNet, Inc. does not assume any obligation to update the information contained herein unless required by applicable law. Please refer to the reports and filings of RadNet, Inc. with the Securities and Exchange Commission for a further discussion of the risks and uncertainties that affect it and its business.

Mark Stolper
Executive Vice President and Chief Financial Officer
RadNet, Inc.
310-445-2800

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB